Treatment of scleromyxedema with 2-chlorodeoxyadenosine

Loretta S. Davis; Salahattin Sanal; Omar P. Sangueza

doi:10.1016/S0190-9622(96)90650-7

Treatment of scleromyxedema with 2-chlorodeoxyadenosine

Loretta S. Davis, Salahattin Sanal, Omar P. Sangueza

Dermatology

Research output: Contribution to journal › Article

21 Scopus citations

Abstract

Scleromyxedema is an unusual skin disease that is characterized by a proliferation of fibroblasts and an accumulation of mucin. Despite experience with multiple forms of therapy, no single agent has proved uniformly beneficial in this condition. We describe a patient with scleromyxedema who was treated successfully with 2-chlorodeoxyadenosine (2-CdA), a purine analog used mainly in the treatment of lymphoproliferative disorders.

Original language	English (US)
Pages (from-to)	288-290
Number of pages	3
Journal	Journal of the American Academy of Dermatology
Volume	35
Issue number	2 II
DOIs	https://doi.org/10.1016/S0190-9622(96)90650-7
State	Published - Aug 1996

ASJC Scopus subject areas

Dermatology

Access to Document

10.1016/S0190-9622(96)90650-7

Fingerprint Dive into the research topics of 'Treatment of scleromyxedema with 2-chlorodeoxyadenosine'. Together they form a unique fingerprint.

Cite this

Davis, L. S., Sanal, S., & Sangueza, O. P. (1996). Treatment of scleromyxedema with 2-chlorodeoxyadenosine. Journal of the American Academy of Dermatology, 35(2 II), 288-290. https://doi.org/10.1016/S0190-9622(96)90650-7

@article{0dce01857e2b4bc79be469dbf2df196e,

title = "Treatment of scleromyxedema with 2-chlorodeoxyadenosine",

abstract = "Scleromyxedema is an unusual skin disease that is characterized by a proliferation of fibroblasts and an accumulation of mucin. Despite experience with multiple forms of therapy, no single agent has proved uniformly beneficial in this condition. We describe a patient with scleromyxedema who was treated successfully with 2-chlorodeoxyadenosine (2-CdA), a purine analog used mainly in the treatment of lymphoproliferative disorders.",

author = "Davis, {Loretta S.} and Salahattin Sanal and Sangueza, {Omar P.}",

year = "1996",

month = aug,

doi = "10.1016/S0190-9622(96)90650-7",

language = "English (US)",

volume = "35",

pages = "288--290",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "Mosby Inc.",

number = "2 II",

}

TY - JOUR

T1 - Treatment of scleromyxedema with 2-chlorodeoxyadenosine

AU - Davis, Loretta S.

AU - Sanal, Salahattin

AU - Sangueza, Omar P.

PY - 1996/8

Y1 - 1996/8

N2 - Scleromyxedema is an unusual skin disease that is characterized by a proliferation of fibroblasts and an accumulation of mucin. Despite experience with multiple forms of therapy, no single agent has proved uniformly beneficial in this condition. We describe a patient with scleromyxedema who was treated successfully with 2-chlorodeoxyadenosine (2-CdA), a purine analog used mainly in the treatment of lymphoproliferative disorders.

AB - Scleromyxedema is an unusual skin disease that is characterized by a proliferation of fibroblasts and an accumulation of mucin. Despite experience with multiple forms of therapy, no single agent has proved uniformly beneficial in this condition. We describe a patient with scleromyxedema who was treated successfully with 2-chlorodeoxyadenosine (2-CdA), a purine analog used mainly in the treatment of lymphoproliferative disorders.

UR - http://www.scopus.com/inward/record.url?scp=0030056419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030056419&partnerID=8YFLogxK

U2 - 10.1016/S0190-9622(96)90650-7

DO - 10.1016/S0190-9622(96)90650-7

M3 - Article

C2 - 8698907

AN - SCOPUS:0030056419

VL - 35

SP - 288

EP - 290

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 2 II

ER -